Point72 Asset Management Takes 5.1% Stake in Alto Neuroscience

Ticker: ANRO · Form: SC 13G · Filed: 2024-02-07T00:00:00.000Z

Sentiment: bullish

Topics: institutional-ownership, insider-buy, new-position

TL;DR

**Point72 just bought 5.1% of Alto Neuroscience, signaling a bullish institutional bet.**

AI Summary

Point72 Asset Management, L.P. has disclosed a significant stake in Alto Neuroscience, Inc., acquiring shared voting and dispositive power over 1,025,000 shares of common stock as of February 6, 2024. This represents a 5.1% ownership stake in the pharmaceutical preparations company. This matters to investors because a major institutional investor like Point72 taking a substantial position can signal confidence in Alto Neuroscience's future prospects, potentially influencing other investors and the stock price.

Why It Matters

A large institutional investment by Point72 Asset Management could be seen as a vote of confidence in Alto Neuroscience, potentially attracting more investor interest and positively impacting its stock valuation.

Risk Assessment

Risk Level: low — This filing indicates a new institutional investment, which is generally a positive signal and does not inherently increase risk for current shareholders.

Analyst Insight

A smart investor would research Alto Neuroscience, Inc.'s fundamentals and recent news to understand why Point72 Asset Management, L.P. took a 5.1% stake, and consider if this institutional confidence aligns with their own investment thesis.

Key Numbers

1,025,000 — Shares Beneficially Owned (Represents the total number of common stock shares Point72 Asset Management, L.P. has shared voting and dispositive power over in Alto Neuroscience, Inc.)
5.1% — Percentage of Class (This is the ownership percentage Point72 Asset Management, L.P. holds in Alto Neuroscience, Inc., indicating a significant stake.)
February 6, 2024 — Date of Event (The specific date when Point72 Asset Management, L.P. reached the threshold requiring this SC 13G filing.)

Key Players & Entities

Point72 Asset Management, L.P. (company) — the reporting person acquiring shares
Alto Neuroscience, Inc. (company) — the subject company whose shares were acquired
1,025,000 (dollar_amount) — number of shares beneficially owned
February 6, 2024 (person) — date of the event requiring the filing
5.1% (dollar_amount) — percentage of class beneficially owned

Forward-Looking Statements

Alto Neuroscience's stock price may experience increased volatility or upward pressure due to institutional interest. (Alto Neuroscience, Inc.) — medium confidence, target: Next 3-6 months
Other institutional investors might follow Point72's lead and initiate or increase their positions in Alto Neuroscience. (Alto Neuroscience, Inc.) — low confidence, target: Next 6-12 months

FAQ

Who is the reporting person in this SC 13G filing?

The reporting person is Point72 Asset Management, L.P., located at 72 Cummings Point Road, Stamford, CT.

What is the name of the issuer whose securities are being reported?

The issuer is Alto Neuroscience, Inc., a pharmaceutical preparations company with its business address at 369 South San Antonio Rd., Los Altos, CA.

How many shares of Alto Neuroscience, Inc. common stock does Point72 Asset Management, L.P. beneficially own?

Point72 Asset Management, L.P. beneficially owns an aggregate amount of 1,025,000 shares of Alto Neuroscience, Inc. common stock.

What percentage of Alto Neuroscience, Inc.'s common stock does this beneficial ownership represent?

This beneficial ownership represents 5.1% of the class of Alto Neuroscience, Inc.'s common stock.

What was the date of the event that triggered this filing?

The date of the event which required the filing of this statement was February 6, 2024.

From the Filing

0000902664-24-001227.txt : 20240207 0000902664-24-001227.hdr.sgml : 20240207 20240207162550 ACCESSION NUMBER: 0000902664-24-001227 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20240207 DATE AS OF CHANGE: 20240207 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-94343 FILM NUMBER: 24604695 BUSINESS ADDRESS: STREET 1: 369 SOUTH SAN ANTONIO RD. CITY: LOS ALTOS STATE: CA ZIP: 94022 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 369 SOUTH SAN ANTONIO RD. CITY: LOS ALTOS STATE: CA ZIP: 94022 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Point72 Asset Management, L.P. CENTRAL INDEX KEY: 0001603466 ORGANIZATION NAME: IRS NUMBER: 465064661 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 72 CUMMINGS POINT ROAD CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-890-2000 MAIL ADDRESS: STREET 1: 72 CUMMINGS POINT ROAD CITY: STAMFORD STATE: CT ZIP: 06902 SC 13G 1 p24-0737sc13g.htm ALTO NEUROSCIENCE, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Alto Neuroscience, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 02157Q109 (CUSIP Number) February 6, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ¨ Rule 13d-1(b) ý Rule 13d-1(c) ¨ Rule 13d-1(d) (Page 1 of 10 Pages) ______________________________ *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (" Act ") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 02157Q109 13G Page 2 of 10 Pages 1 NAME OF REPORTING PERSON Point72 Asset Management, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 1,025,000 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 1,025,000 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,025,000 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.8% 12 TYPE OF REPORTING PERSON PN CUSIP No. 02157Q109 13G Page 3 of 10 Pages 1 NAME OF REPORTING PERSON Point72 Capital Advisors, Inc. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 1,025,000 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 1,025,000 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,025,000 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.8% 12 TYPE OF REPORTING PERSON CO CUSIP No. 02157Q109 13G Page 4 of 10 Pages 1 NAME OF REPORTING PERSON Point72 Biotech Private Investments, LLC 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x 3 SEC USE ONLY 4 CITIZ